Lineage Cell Therapeutics, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Lineage Cell Therapeutics, Inc. (LCTX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $24.00K.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$7.00K, a 153.85% decline year-over-year.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $6.00K.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$8.00K.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$4.00K.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$153.00K.
- Lineage Cell Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$2.19M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $24.00K 10-Q · filed 2026-08-06 | $17.00K derived: sum of 3 quarters · filed 2026-08-06 | $23.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $24.00K 10-Q · filed 2026-05-12 | $17.00K derived: sum of 2 quarters · filed 2026-05-12 | $23.00K derived: sum of 3 quarters · filed 2026-05-12 | $21.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.00K derived: sum of 2 quarters · filed 2026-03-05 | -$3.00K derived: sum of 3 quarters · filed 2026-08-06 | -$8.00K 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $6.00K 10-Q · filed 2025-11-06 | $4.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.00K 10-Q · filed 2025-11-06 | $12.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$2.00K 10-Q · filed 2026-08-06 | -$7.00K 10-Q · filed 2026-08-06 | $6.00K derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$5.00K 10-Q · filed 2026-05-12 | $8.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.00K derived: sum of 3 quarters · filed 2026-05-12 | -$4.00K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.00K derived: sum of 3 quarters · filed 2026-03-05 | -$4.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$6.00K 10-Q · filed 2025-11-06 | -$12.00K derived: sum of 2 quarters · filed 2025-11-06 | -$17.00K 10-Q · filed 2025-11-06 | -$23.00K derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | -$6.00K 10-Q · filed 2025-08-12 | -$11.00K 10-Q · filed 2025-08-12 | -$17.00K derived: sum of 3 quarters · filed 2025-08-12 | -$54.00K derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$5.00K 10-Q · filed 2025-05-13 | -$11.00K derived: sum of 2 quarters · filed 2025-05-13 | -$48.00K derived: sum of 3 quarters · filed 2025-05-13 | -$198.00K derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$43.00K derived: sum of 2 quarters · filed 2025-03-10 | -$193.00K derived: sum of 3 quarters · filed 2025-03-10 | -$153.00K 10-K · filed 2025-03-10 | ||
| 2023-09-30 | -$37.00K 10-Q · filed 2024-11-14 | $37.00K 10-Q · filed 2023-11-09 | -$187.00K derived: sum of 2 quarters · filed 2024-11-14 | -$147.00K 10-Q · filed 2024-11-14 | $147.00K 10-Q · filed 2023-11-09 | -$4.02M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$150.00K 10-Q · filed 2024-08-08 | -$110.00K 10-Q · filed 2024-08-08 | -$3.98M derived: sum of 3 quarters · filed 2024-08-08 | -$3.75M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $40.00K 10-Q · filed 2024-05-09 | -$3.83M derived: sum of 2 quarters · filed 2024-05-09 | -$3.60M derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$3.64M derived: sum of 2 quarters · filed 2024-03-07 | -$2.19M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $233.00K 10-Q · filed 2023-11-09 | $1.68M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |